Clinical bottom line
Anti-fibrotic therapies, primarily developed for idiopathic pulmonary fibrosis (IPF), are emerging as potential treatment options for post-COVID-19 pulmonary fibrosis, a complication increasingly recognized in survivors of severe SARS-CoV-2 infection. Current evidence, including systematic reviews and mini-reviews, suggests that these agents may help slow fibrotic progression and improve clinical outcomes in select patients with post-COVID fibrosis. However, robust randomized controlled trial data remain limited, and the optimal timing, patient selection, and long-term benefits of anti-fibrotic therapy in this context are not yet established. Clinicians should consider anti-fibrotic therapy as a putative option within a multidisciplinary management plan, pending further validation.
What the evidence shows
Post-COVID-19 pulmonary fibrosis is characterized by persistent fibrotic changes on imaging and impaired lung function following acute infection, particularly in patients with severe or critical illness. Chakraborty et al. (2021) provided an early mini-review highlighting the mechanistic rationale for repurposing anti-fibrotic agents such as pirfenidone and nintedanib, which inhibit pathways involved in fibroblast proliferation and extracellular matrix deposition. These agents have demonstrated efficacy in slowing disease progression in IPF, a fibrotic lung disease with some pathophysiological overlap with post-COVID fibrosis.
More recently, Shu et al. (2024) conducted a systematic review and meta-analysis evaluating the impact of anti-fibrotic medications on post-COVID-19 pulmonary fibrosis. Their analysis incorporated observational studies and small clinical cohorts, reporting that anti-fibrotic therapy was associated with improved radiological fibrosis scores and stabilization or modest improvement in pulmonary function tests compared to no treatment. However, the included studies were heterogeneous in design, patient populations, and treatment regimens, limiting definitive conclusions.
Evidence from IPF studies remains relevant, as summarized in multiple reviews of anti-fibrotic therapy and lung transplant outcomes (2022–2023). These reviews underscore that anti-fibrotics reduce lung function decline and may improve survival in fibrotic lung diseases, supporting their potential utility in post-COVID fibrosis (multiple reviews, 2022–2023). Robertson et al. (2023) further confirmed real-world survival benefits of anti-fibrotic therapy in IPF, reinforcing the translational rationale for their use in post-COVID fibrosis.
Caveats and uncertainty
The current evidence base for anti-fibrotic therapy in post-COVID pulmonary fibrosis is largely derived from observational studies, retrospective analyses, and extrapolation from IPF data. There is a paucity of large-scale randomized controlled trials specifically addressing this indication, and the natural history of post-COVID fibrosis remains incompletely defined. The heterogeneity in patient phenotypes, timing of therapy initiation, and outcome measures complicates interpretation.
Safety and tolerability profiles of anti-fibrotics in the post-COVID population, who may have multiple comorbidities and ongoing inflammatory processes, require further characterization. Additionally, the potential for spontaneous fibrosis resolution in some patients raises questions about the optimal timing and duration of therapy.
Finally, the impact of anti-fibrotic therapy on long-term functional outcomes, quality of life, and healthcare resource utilization in post-COVID fibrosis has not been systematically studied.
How this may change practice
Clinicians managing patients with persistent fibrotic lung changes after COVID-19 should maintain a high index of suspicion for progressive fibrosis and consider multidisciplinary evaluation including pulmonology, radiology, and rehabilitation services. While awaiting more definitive trial data, anti-fibrotic therapy may be considered on a case-by-case basis for patients demonstrating progressive fibrosis and functional decline, particularly when alternative causes have been excluded.
Early identification of candidates for therapy and close monitoring of treatment response using pulmonary function tests and imaging are advisable. Shared decision-making with patients regarding the potential benefits, risks, and uncertainties of anti-fibrotic treatment is essential.
Ongoing and future clinical trials will be critical to establish evidence-based guidelines for anti-fibrotic use in post-COVID fibrosis, including patient selection criteria, timing, dosing, and combination with other supportive therapies.